Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients

Abstract

Critically ill COVID-19 patients present an inflammatory and procoagulant status with a high rate of relevant macro- and microvascular thrombosis. Furthermore, high rates of heparin resistance have been described; yet, individualized anticoagulation by drug monitoring has not been sufficiently researched. We analyzed data from critically ill COVID-19 patients treated at Innsbruck Medical University Hospital with routinely adapted low-molecular-weight heparin (LMWH) doses according to anti-Xa peak levels, and regularly performed ClotPro analyses (a viscoelastic hemostatic whole blood test). A total of 509 anti-Xa peak measurements in 91 patients were categorized as below (<0.008 IU/mL/mg), within (0.008–0–012 IU/mL/mg) or above (> 0.012 IU/mL/mg) expected ranges with respect to the administered LMWH doses. Besides intergroup comparisons, correlations between anti-Xa levels and ClotPro clotting times (CTs) were performed (226 time points in 84 patients). Anti-Xa peak levels remained below the expected range in the majority of performed measurements (63.7%). Corresponding patients presented with higher C-reactive protein and D-dimer but lower antithrombin levels when compared with patients achieving or exceeding the expected range. Consequently, higher enoxaparin doses were applied in the sub-expected anti-Xa range group. Importantly, 47 (51.6%) patients switched between groups during their intensive care unit (ICU) stay. Anti-Xa levels correlated weakly with IN test CT and moderately with Russell's viper venom (RVV) test CT. Critically ill COVID-19 patients present with a high rate of LMWH resistance but with a variable LMWH response during their ICU stay. Therefore, LMWH–anti-Xa monitoring seems inevitable to achieve adequate target ranges. Furthermore, we propose the use of ClotPro's RVV test to assess the coagulation status during LMWH administration, as it correlates well with anti-Xa levels but more holistically reflects the coagulation cascade than anti-Xa activity alone.

Keywords

COVID-19 - critically ill - heparin resistance - anti-Xa - viscoelastic test

Publication History

Article published online:
29 September 2022

• References

• 1 Suh YJ, Hong H, Ohana M. et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021; 298 (02) E70-E80
• 2 Gratz J, Wiegele M, Maleczek M. et al. Risk of clinically relevant venous thromboembolism in critically ill patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne) 2021; 8: 647917
• 3 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020; 383 (02) 120-128
• 4 Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA. et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020; 18 (06) 1517-1519
• 5 Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020; 8 (07) 681-686
• 6 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
• 7 Goligher EC, Bradbury CA, McVerry BJ. et al; REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 777-789
• 8 Sadeghipour P, Talasaz AH, Rashidi F. et al; INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical trial. JAMA 2021; 325 (16) 1620-1630
• 9 Streng AS, Delnoij TSR, Mulder MMG. et al. Monitoring of unfractionated heparin in severe COVID-19: an observational study of patients on CRRT and ECMO. TH Open 2020; 4 (04) e365-e375
• 10 White D, MacDonald S, Bull T. et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020; 50 (02) 287-291
• 11 Novelli C, Borotto E, Beverina I, Punzi V, Radrizzani D, Brando B. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. Int J Lab Hematol 2021; 43 (06) 1284-1290
• 12 Wu T, Xia X, Chen W, Fu J, Zhang J. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and meta-analysis. J Clin Pharm Ther 2020; 45 (04) 602-608
• 13 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (09) 673-684
• 14 Gorham J, Taccone FS, Hites M. Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment. Expert Opin Drug Metab Toxicol 2022; 18 (03) 177-187
• 15 AWMF. S3-Leitlinie - Empfehlungen zur stationären Therapie von Patienten mit COVID-19. 113/001. 2022 . Accessed June 1, 2022 at: https://www.awmf.org/leitlinien/detail/ll/113-001LG.html
• 16 Panel C-TG. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. 2022 . Accessed June 1, 2022 at: https://www.covid19treatmentguidelines.nih.gov/
• 17 Feuring M, Wehling M, Schultz A. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study. Clin Exp Pharmacol Physiol 2011; 38 (11) 783-786
• 18 Pratt J, Crispin P. Screening test for direct oral anticoagulants with the dilute Russell viper venom time. Eur J Haematol 2018; 100 (06) 567-574
• 19 Suzuki K, Katori N, Kimura Y. et al. Evaluation of the effect of apixaban using a viscoelastic coagulation assay with Russell's viper venom reagent. JA Clin Rep 2021; 7 (01) 42
• 20 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71 (03) 300-304
• 21 Raut S, Gaffney PJ. Interaction of heparin with fibrinogen using surface plasmon resonance technology: investigation of heparin binding site on fibrinogen. Thromb Res 1996; 81 (04) 503-509
• 22 Bendetowicz AV, Kai H, Knebel R. et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma–a study in human volunteers. Thromb Haemost 1994; 72 (05) 705-712
• 23 Schoen P, Lindhout T, Franssen J, Hemker HC. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III–effect of platelet factor 4. Thromb Haemost 1991; 66 (04) 435-441
• 24 Dörffler-Melly J, de Jonge E, Pont AC. et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359 (9309): 849-850
• 25 Haas CE, Nelsen JL, Raghavendran K. et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005; 59 (06) 1336-1343 , discussion 1343–1344
• 26 Croles FN, Lukens MV, Mulder R, de Maat MPM, Mulder AB, Meijer K. Monitoring of heparins in antithrombin-deficient patients. Thromb Res 2019; 175: 8-12
• 27 Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res 2016; 118 (09) 1392-1408
• 28 Lazzaroni MG, Piantoni S, Masneri S. et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev 2021; 46: 100745
• 29 Bachler M, Bösch J, Stürzel DP. et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth 2021; 126 (03) 590-598
• 30 Samuel S, Allison TA, Sharaf S. et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther 2016; 41 (05) 499-502
• 31 Agnelli G, Iorio A, Renga C. et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92 (10) 2819-2824
• 32 Vatsyayan R, Kothari H, Mackman N, Pendurthi UR, Rao LV. Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor. PLoS One 2014; 9 (08) e103505
• 33 Westmark PR, Tanratana P, Sheehan JP. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX. J Thromb Haemost 2015; 13 (06) 1053-1063
• 34 Derkx FH, Bouma BN, Schalekamp MA. Prorenin-renin conversion by the contact activation system in human plasma: role of plasma protease inhibitors. J Lab Clin Med 1984; 103 (04) 560-573
• 35 Blasi A, Beltran J, Pereira A. et al. An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation. Transfusion 2012; 52 (09) 1989-1998
• 36 Wang SC, Shieh JF, Chang KY. et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010; 42 (07) 2590-2593
• 37 Spiezia L, Boscolo A, Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120 (06) 998-1000
• 38 Wright FL, Vogler TO, Moore EE. et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 2020; 231 (02) 193-203.e1
• 39 Pavoni V, Gianesello L, Conti D. et al. “In less than no time”: feasibility of rotational thromboelastometry to detect anticoagulant drugs activity and to guide reversal therapy. J Clin Med 2022; 11 (05) 1407
• 40 Govers-Riemslag JWP, Konings J, Cosemans JMEM. et al. Impact of deficiency of intrinsic coagulation factors XI and XII on ex vivo thrombus formation and clot lysis. TH Open 2019; 3 (03) e273-e285
• 41 Bachler M, Niederwanger C, Hell T. et al. Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients. J Thromb Thrombolysis 2019; 48 (03) 466-474
• 42 Englert H, Rangaswamy C, Deppermann C. et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine 2021; 67: 103382
• 43 Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent. Blood Coagul Fibrinolysis 2010; 21 (03) 256-261
• 44 Groene P, Wagner D, Kammerer T. et al. Viscoelastometry for detecting oral anticoagulants. Thromb J 2021; 19 (01) 18